Partnering Opportunities
In addition to those products already partnered or licensed, Biota has a number of projects approaching key milestones of commercial interest:
Biota, together with our Japanese based partner, Daiichi Sankyo, have developed
a second generation of inhaled antiviral compounds for influenza, called long-acting inhaled neuraminidase inhibitors (LANI), which are currently available for licensing.
The lead product, laninamivir, has been shown to be effective in Phase III clinical trials in Asia.
Biota's human rhinovirus (HRV) drug for the prevention and treatment of one of the
major causes of the common cold, BTA798, has completed Phase I and Phase IIa clinical trials. Biota is prepared to accept early expressions of interest from partners interested in this program.
Readers who would like to know more about these or other potential opportunities, should contact Biota's Vice President Business Development, Dr Leigh Farrell on
+61 (3) 9915 3700 or l.farrell@biota.com.au.